Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

Bastian von TresckowDepartment I of Internal Medicine;Center for Molecular Medicine, University Hospital Cologne, Cologne, GermanyCorrespondence[email protected]

Boris BoellDepartment I of Internal Medicine;Center for Molecular Medicine, University Hospital Cologne, Cologne, Germany

Dennis EichenauerDepartment I of Internal Medicine

Denissa BeschornerDepartment I of Internal Medicine

Stefan KnopDivision of Hematology, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

Maria-Elisabeth GoebelerDivision of Hematology, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

Jens Marcus ChemnitzDepartment I of Internal Medicine

Michael HallekDepartment I of Internal Medicine

Andreas EngertDepartment I of Internal Medicine

Kai HuebelDepartment I of Internal Medicine

show all

References

Markman B, Capdevila J, Elez E, et al. New trends in epidermal growth factor receptor-directed monoclonal antibodies. Immunotherapy 2009;1:965–982.
PubMed Web of Science ®Google Scholar
Mahtouk K, Hose D, Reme T, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 2005;24:3512–3524.
PubMed Web of Science ®Google Scholar
Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004;103:1829–1837.
PubMed Web of Science ®Google Scholar
Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20: 1467–1473.
PubMed Web of Science ®Google Scholar
Boll B, Eichenauer DA, Von Tresckow B, et al. Activity of cetuximab as single agent in a patient with relapsed multiple myeloma. Leuk Lymphoma 2010;51:562–564.
PubMed Web of Science ®Google Scholar
Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nurs 2005;9:332–338.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date